Where does Peter MacCallum Cancer Institute rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Peter MacCallum Cancer Institute ranks #24,990 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Peter MacCallum Cancer Institute hold?

Peter MacCallum Cancer Institute holds 11 US utility patents granted between 2015 and 2025, spanning 9 technology areas.

What is Peter MacCallum Cancer Institute's Innovation Score?

Peter MacCallum Cancer Institute has an Innovation Score of 45.8 out of 100 (top 22% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Peter MacCallum Cancer Institute focus on?

Peter MacCallum Cancer Institute's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 8 patents, ranking #2,286 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Peter MacCallum Cancer Institute's patent grant rate increasing or decreasing?

Peter MacCallum Cancer Institute's recent grant velocity is -57% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Peter MacCallum Cancer Institute's patents?

Peter MacCallum Cancer Institute's patents average 11.1 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Peter MacCallum Cancer Institute patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Peter MacCallum Cancer Institute

USPTO PatentsView assignee record - 11 granted patents across 9 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Peter ranks #24,990 of 49,997 tracked US assignees by granted-patent volume, with 11 patents across 9 technology areas.

#24,990
of 49,997 US assignees by volume: Top 22%
by Innovation Score (45.8/100): 11.1
avg claims per patent: -57%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R24990 · Foreign Corporation #24,990 · 11 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-PAR · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 11 grants
MID-PACK #24,990/49,997
PHOTO-FINISH Peptilogics
CPC-NARROW A61P · 9 areas
INNOV-PAR 45.8/100
CLAIMS-PAR 11.1 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -57% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Peptilogics, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Peter’s 45.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.6 pts (19%) Velocity 20.0 pts (44%) Breadth 10.6 pts (23%) Claim depth 6.7 pts (15%)

Qualcomm Incorporated · highest

85
Peter MacCallum… · this assignee

46
3D Lighting… · lowest

7

What this shows Peter's Innovation Score is 45.8/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Peter?

Each dot is one of Peter’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Peter’s own 11.1 claims/patent is at or below the 19.4 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Peter vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Peter's grants concentrate

Peter MacCallum Cancer Institute is a focused PatentsView assignee: 9 CPC subclasses with 72.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2018 (4 grants) versus a trough of 1 in 2015. By volume, Peter sits between Peptilogics, Inc. and Phoenix Technologies Ltd..

Peter's three-year grant acceleration

Peter MacCallum Cancer Institute shows 3 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Peptilogics

11
Perceptimed

11
Percutaneous Card…

11
Pericom Semicondu…

11
Phagenesis

11
Pham Holdings

11
Philter Labs Inco…

11
Phoenix

11
Peter Maccallum C… ◀

11

What this shows Peter holds 11 patents at rank #24,996, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Peter

By rank, the assignees closest to #24,996 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Peter's primary technology class.

Peter's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Peter MacCallum Cancer Institute patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	9.1%
2017	2	18.2%
2018	4	36.4%
2022	1	9.1%
2023	1	9.1%
2024	1	9.1%
2025partial year	1	9.1%

Which technologies does Peter MacCallum Cancer Institute patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 5

C07K - Peptides 4

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 2

C07D - Heterocyclic Compounds 2

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 1

Y02A - Technologies FOR Adaptation TO Climate Change 1

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Peter MacCallum Cancer Institute's patent record in context - here's where to go next.

Peter MacCallum Cancer Institute's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 72.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #24,990 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Peter MacCallum Cancer Institute against Peptilogics, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.